What is the address of PHARMXPERTISE?

The registered office of PHARMXPERTISE is located at Rue des Grands Joncs 2, 5336 Assesse.

Is PHARMXPERTISE still active?

Yes. According to the CBE (30 October 2026) PHARMXPERTISE is active, legal situation “Normale toestand”, started on 27 January 2020.

Is PHARMXPERTISE registered on Peppol?

Yes, PHARMXPERTISE is registered on the Peppol network with ID 0208:0742556675.

What is the enterprise number of PHARMXPERTISE?

The enterprise number of PHARMXPERTISE is BE0742556675.

When was PHARMXPERTISE founded?

PHARMXPERTISE was founded on 27 January 2020.

Who are the directors of PHARMXPERTISE?

According to the 2025 annual accounts, the directors of PHARMXPERTISE are: JONATHAN DOUXFILS.

Is PHARMXPERTISE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMXPERTISE make in 2025?

PHARMXPERTISE posted a profit after taxes of € 19,228 in financial year 2025.

What is the revenue of PHARMXPERTISE?

As a small company, PHARMXPERTISE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 61,703.

PHARMXPERTISE (Private Limited) - Assesse - BE0742556675

Q: What does PHARMXPERTISE do?

PHARMXPERTISE is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 27 January 2020, 1 establishment.

Dossier PHARMXPERTISE, printed on 30 October 2026 from databakkes.be/en/0742556675/pharmxpertise. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMXPERTISE from Assesse, company number BE0742556675, closed financial year 2025 with a result of € 19,228 after tax. For that financial year PHARMXPERTISE recorded a gross margin of € 61,703 and equity of € 155,143. Compared with financial year 2024, the result moved from € 21,718 to € 19,228. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.

What it is worth Growing

€ 155,143

▲ 14% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 19,228

▼ 11% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 31,258

▲ 198% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 152,143.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 40,575

▼ 13% vs 2024

Of which on lease € 22,203.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 22,519

▼ 24% vs 2024

€ 7,322 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 4,207

▲ 33% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 57

▼ 98% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 47,493 Gross margin 2022: € 47,493 First fiscal year in the series	€ 56,650 Gross margin 2023: € 56,650 ▲ 19% vs 2022 (€ 47,493) Favourable step	€ 46,691 Gross margin 2024: € 46,691 ▼ 18% vs 2023 (€ 56,650) Unfavourable step	€ 61,703 Gross margin 2025: € 61,703 ▲ 32% vs 2024 (€ 46,691) Favourable step	▲ 32%
Profit after taxes	€ 34,996 Profit after taxes 2022: € 34,996 First fiscal year in the series	€ 35,424 Profit after taxes 2023: € 35,424 ▲ 1% vs 2022 (€ 34,996) Favourable step	€ 21,718 Profit after taxes 2024: € 21,718 ▼ 39% vs 2023 (€ 35,424) Unfavourable step	€ 19,228 Profit after taxes 2025: € 19,228 ▼ 11% vs 2024 (€ 21,718) Unfavourable step	▼ 11%
Equity	€ 118,772 Equity 2022: € 118,772 First fiscal year in the series	€ 154,196 Equity 2023: € 154,196 ▲ 30% vs 2022 (€ 118,772) Favourable step	€ 135,914 Equity 2024: € 135,914 ▼ 12% vs 2023 (€ 154,196) Unfavourable step	€ 155,143 Equity 2025: € 155,143 ▲ 14% vs 2024 (€ 135,914) Favourable step	▲ 14%
Total debts	€ 45,662 Total debts 2022: € 45,662 First fiscal year in the series	€ 42,323 Total debts 2023: € 42,323 ▼ 7% vs 2022 (€ 45,662) Favourable step	€ 75,361 Total debts 2024: € 75,361 ▲ 78% vs 2023 (€ 42,323) Unfavourable step	€ 31,663 Total debts 2025: € 31,663 ▼ 58% vs 2024 (€ 75,361) Favourable step	▼ 58%
Cash	€ 12,571 Cash 2022: € 12,571 First fiscal year in the series	€ 9,391 Cash 2023: € 9,391 ▼ 25% vs 2022 (€ 12,571) Unfavourable step	€ 10,476 Cash 2024: € 10,476 ▲ 12% vs 2023 (€ 9,391) Favourable step	€ 31,258 Cash 2025: € 31,258 ▲ 198% vs 2024 (€ 10,476) Favourable step	▲ 198%
Retained profit	€ 115,772 Retained profit 2022: € 115,772 First fiscal year in the series	€ 151,196 Retained profit 2023: € 151,196 ▲ 31% vs 2022 (€ 115,772) Favourable step	€ 132,914 Retained profit 2024: € 132,914 ▼ 12% vs 2023 (€ 151,196) Unfavourable step	€ 152,143 Retained profit 2025: € 152,143 ▲ 14% vs 2024 (€ 132,914) Favourable step	▲ 14%
Dividend	€ 5,000 Dividend 2022: € 5,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 5,000) Unchanged	€ 40,000 Dividend 2024: € 40,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 40,000) Unchanged	▼ 100%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 36,261 Bank debt 2023: € 36,261 Unchanged (€ 0) Unfavourable step	€ 29,536 Bank debt 2024: € 29,536 ▼ 19% vs 2023 (€ 36,261) Favourable step	€ 22,519 Bank debt 2025: € 22,519 ▼ 24% vs 2024 (€ 29,536) Favourable step	▼ 24%
Balance sheet total	€ 164,434 Balance sheet total 2022: € 164,434 First fiscal year in the series	€ 196,519 Balance sheet total 2023: € 196,519 ▲ 20% vs 2022 (€ 164,434) Unchanged	€ 211,275 Balance sheet total 2024: € 211,275 ▲ 8% vs 2023 (€ 196,519) Unchanged	€ 186,806 Balance sheet total 2025: € 186,806 ▼ 12% vs 2024 (€ 211,275) Unchanged	▼ 12%

Key figures of PHARMXPERTISE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMXPERTISE?

What happened at PHARMXPERTISE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 18, 2026 New annual accounts for financial year 2025: profit of € 19,228 (▼ 11% vs 2024). filed late Source: NBB ↗
Jan 27, 2020 New establishment in Assesse. KBO
Jan 27, 2020 Start of the company according to the CBE. KBO
2020 JONATHAN DOUXFILS became a director. NBB

In short

From € 34,996 profit in 2022 to € 19,228 profit in 2025.

Paid € 39,742 in corporate taxes since 2022.

Best year ever: 2023, with € 35,424 profit.

Paid out € 45,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

JONATHAN DOUXFILS 100%

PHARMXPERTISE

Behind PHARMXPERTISE is JONATHAN DOUXFILS. The shares are held by JONATHAN DOUXFILS (100%).

Directors

According to the 2025 annual accounts

JONATHAN DOUXFILS

Director

Owns 100% directly

since 2020

Shareholders

JONATHAN DOUXFILS · director

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Grands Joncs 2

5336 Assesse

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PharmNutri Care

€ 42,560 gross margin · 2025

CEDECE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0742.556.675

VAT number

BE 0742.556.675

Registered office

Rue des Grands Joncs 2, 5336 Assesse

Names & denominations

PHARMXPERTISE

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 January 2020

Peppol

Active · Active since 1 Jan 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMXPERTISE

Financials

What happened to PHARMXPERTISE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions